NCT04849741Phase 3Active not recruiting

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-08-22Actual
Enrollment · participants54Actual
Source updated2026-08-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 22 Aug 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview